东阿阿胶股份有限公司2025年半年度报告摘要

Core Points - The company has approved a cash dividend distribution plan of 12.69 yuan per 10 shares, based on a total of 643,976,824 shares, without any stock bonus or capital reserve conversion [2][16][34] - The company has not undergone any changes in its controlling shareholder or actual controller during the reporting period [4][5] - The company plans to acquire 70% of Dongfeng Majiji Pharmaceutical Co., Ltd. for approximately 33.79852 million yuan, which will become a subsidiary [19] - The company also intends to acquire 80% of Inner Mongolia Alashan Congrong Group Co., Ltd. for about 59.965686 million yuan and will increase its capital by 35 million yuan [21] - The board of directors and the supervisory board have confirmed that the 2025 semi-annual report is accurate and complete, reflecting the company's actual operating conditions [15][33] Company Overview - The company is engaged in the production and sale of traditional Chinese medicine products, with a focus on health and wellness [3] - The company has a total of 643,976,824 shares outstanding, with no changes in major shareholders during the reporting period [3][4] - The company has not issued any preferred shares during the reporting period [6] Important Matters - No significant matters were reported during the period [7] - The company has confirmed that all board meetings and supervisory meetings were conducted in compliance with relevant laws and regulations [13][32]